Insulin resistance and its contribution to colon carcinogenesis

Experimental Biology and Medicine

Volumn 228, Issue 4, 2003, Pages 396-405

  Komninou, Despina ^a   Ayonote, Alexis ^b   Richie Jr , John P ^a   Rigas, Basil ^a,b  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Aging; Carcinogenesis; Colon cancer; IGF 1; Insulin resistance

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; SOMATOMEDIN; SOMATOMEDIN C;

AGING; CANCER RISK; COLON CANCER; COLON CARCINOGENESIS; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; COLON TUMOR; DIET; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

COLONIC NEOPLASMS; DIET; HUMANS; INSULIN RESISTANCE; SOMATOMEDINS;

EID: 0038100271     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020322800410     Document Type: Short Survey

References (107)

1. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 6:164-179, 1995.
2. McKeown-Essen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomark Prev 3:687-695, 1994.
3. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes 22:345-354, 1999.
4. Flegal KM. The obesity epidemic in children and adults: current evidence and research issues. Med Sci Sports 31:S509-S514, 1999.
5. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK. SEER Cancer Statistics Review 1973-1997, National Cancer Institute. NIH Pub. No. 00-2789. Bethesda, MD, 2002.
6. Schulz JH. The Economics of Aging. New York: Auburn House, 1992.
7. Consensus development conference on insulin resistance: American Diabetes Association. Diabetes Care 21:310-314, 1998.
8. Gavin J, Kagan S. Vascular disease prevention in patients with diabetes. Diabetes Obes Metab 2:S25-S36, 2000.
9. Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol 16:779-789, 2000.
10. Bruce WR, Wolever TMS, Giacca A. Mechanisms linking diet and colorectal cancer. The possible role of insulin resistance. Nutr Cancer 37:19-26, 2000.
11. Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988.
12. Rao G. Insulin resistance syndrome. Am Fam Physician 63:1559-1563, 2001.
13. Andres R, Swerdoff R, Pozefsky T, Coleman D. Manual feedback technique for the control of blood glucose concentration, In: Skeggs LT, Ed. Automation in Analytical Chemistry. New York: Medicaid, pp486-491, 1966.
14. Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979.
15. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79:790-800, 1987.
16. Laakso M. How good a marker is insulin level for insulin resistance. Am J Epidemiol 137:959-965, 1993.
17. American Diabetes Association. Task force on standardization of insulin assay (task force report). Diabetes 45:242-256, 1996.
18. Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet 346:120-121, 1995.
19. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410, 2000.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Tur RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28:412-419, 1985.
21. Trevisan M, Liu J, Bahsas FB, Allessandro M. Syndrome X and mortality: a population-based study. Am J Epidemiol 148:958-966, 1998.
22. Wilson PW, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol 11:119-123, 2002.
23. Ma XH, Muzumdar R, Yang XM, Gabriely I, Berger R and Barzilai N. Aging is associated with resistance to effects of leptin on fat distribution and insulin action. J Gerontol A Biol Sci Med Sci 57:B225-B231, 2002.
24. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86:3574-3578, 2001.
25. Barzilai N, Rossetti L. Age-related changes in body composition are associated with hepatic insulin resistance in conscious rats. Am J Physiol 33:E930-E936, 1996.
26. Reaven GM. Insulin-stimulated glucose disposal in patients with type I (IDI) and type (NIDDM) diabetes mellitus. Adv Exp Med Biol 189:129-136, 1985.
27. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK. (1994) SEER Cancer Statistics Review, 1973-1991; Tables and Graphs. NCI, NIH Publication No. 94-2789, Bethesda, MD.
28. Komninou D, Leutzinger Y, Reddy BS, Richie JP Jr. Effects of aging and methionine restriction on preneoplastic aberrant crypt foci formation in rat colon. Proc Am Assoc Cancer Res 37:282, 1996.
29. Barzilai N, Rossetti L. The relationship between changes in body composition and insulin responsiveness in models of the aging rat. Am J Physiol 269:E591-E597, 1995.
30. Greenberg JA, Boozer CN. The leptin-fat ratio is constant, and leptin may be part of two feedback mechanisms for maintaining the body fat set point in non-obese male Fischer 344 rats. Horm Metab Res 31:525-532, 1999.
31. Smith D, Bronson R. Clinical chemistry and hematology profiles of the aging rat. Lab Animal 21:32-46, 1992.
32. Weindruch RH, Walford RL. The Retardation of Aging and Disease by Dietary Restriction, Springfield, IL: CC. Thomas Co., 1988.
33. Steinbach G, Kumar SP, Reddy BS, Lipkin M, Holt PR. Effects of caloric restriction and dietary fat on epithelial cell proliferation in rat colon. Cancer Res 53:2745-2749, 1993.
34. Koohestani N, Tran TT, Lee W, Wolever TM, Bruce WR. Insulin resistance and promotion of aberrant crypt foci in the colons of rats on a high-fat diet. Nutr Cancer 29:69-76, 1997.
35. Koohestani N, Chia MC, Pham NA, Tran TT, Minkin S, Wolever TM, Bruce WR. Aberrant crypt foci promotion and glucose intolerance: correlation in the rat across diets differing in fat, n-3 fatty acid and energy. Carcinogenesis 19:1679-1684, 1998.
36. Lasko CM, Good CK, Adam J, Bird RP. Energy restriction modulates the development of advanced preneoplastic lesions depending on the level of fat in the diet. Nutr Cancer 33:69-75, 1999.
37. Man ZW, Hirashima T, Mori S, Kawano K. Decrease in triglyceride accumulation in tissues by restricted diet and improvement of diabetes in Otsuka Long-Evans Tokushim fatty rats, a non-insulin-dependent diabetes model. Metabolism 49:108-114, 2000.
38. Orentreich N, Matias JR, DeFelice A, Zimmerman JA. Low methionine ingestion by rats extends life span. J Nutr 123:269-274, 1993.
39. Richie JP Jr, Leutzinger Y, Parthasarathy S, Malloy V, Orentreich N, Zimmerman JA. Methionine restriction increases blood glutathione and longevity in F344 rats. FASEB J 8:1302-1307, 1994.
40. Lang CA, Naryshkin S, Schneider DL, Mills BJ, Lindeman RD. Low blood glutathione levels in healthy aging adults. J Lab Clin Med 120:720-725, 1992.
41. Matsubara LS, Machado PEA. Age-related changes of glutathione content, glutathione reductase and glutathione peroxidase activity of human erythrocytes. Brazilian J Med Biol Res 24:449-454, 1991.
42. Al-Turk WA, Stohs SJ, El-Rashidy FH, Othman S. Changes in glutathione and its metabolizing enzymes in human erythrocytes and lymphocytes with age. Pharmacology 39:13-16, 1987.
43. Murakami K, Kondo T, Ohtsuka Y, Shimada M, Kawakami Y. Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism 38:753-758, 1989.
44. Ames BN. Endogenous DNA damage as related to nutrition and aging. In: Ingram DK, Baker GT, Shock NW, Eds. The Potential for Nutritional Modulation of Aging Processes. Westport, CT: Food and Nutrition Press, pp51-66, 1991.
45. Barzilai N, Gupta G. Revisiting the role of fat mass in the life extension induced by caloric restriction. J Gerontol Biol Sci 54A:B89-B96, 1999.
46. Shimokata H, Tobin JD, Muller DC, Elahi D, Coon PJ, Andres R. Studies in the distribution of body fat: effects of age sex, amd obesity. J Gerontol 44:M66-M73, 1989.
47. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143, 1991.
48. Barzilai N, She BQ, Liu P, Vuguin J, Cohen P, Rossetti L. Surgical removal of visceral fat in rats reverses hepatic insulin resistance. Diabetes 48:94-98, 1999.
49. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91, 1996.
50. Ahren B, Mansson S, Gingerich R, Havel P. Regulation of plasma leptin in mice: influence of age, high-fat diet, and fasting. Am J Physiol 273:R113-R120, 1997.
51. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 17:555-560, 1999.
52. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860-867, 1997.
53. Bruce WR, Giacca A, Medline A. Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol Biomark Prev 9:1271-1279, 2000.
54. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomark Prev 5:1013-1015, 1996.
55. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62:1030-1035, 2002.
56. Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 44:704-708, 1999.
57. Hoeflich A, Yang Y, Huber S, Rascher W, Koepf G, Blum WF, Heinz-Erian P, Kolb HJ, Keiss W. Expression of IGFBP-2,-3 and -4, mRNA during differentiation of Caco-2 colon epithelial cells. Am J Physiol 271:E922-E931, 1996.
58. Zenilman ME, Graham W. Insulin-like growth factor-1 receptor messenger RNA in the colon is unchanged during neoplasia. Cancer Invest 15:1-7, 1997.
59. Adenis A, Peyrat JP, Hecquet B, Delobelle A, Depadt G, Quandalle P, Bonneterre J, Demaille A. Type 1 insulin-like growth factor receptors in human colorectal cancer. Eur J Cancer 31A:50-55, 1995.
60. Mishra L, Bass B, Ooi BS, Sidawy A, Korman L. Role of insulin-like growth factor-1 (IGF-1) receptor, IGF-1, IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res 8:473-479, 1998.
61. Giovannucci E. Insulin, insulin-like growth factors and colon cancer. J Nutr 131:3109S-3120S, 2001.
62. Ma J, Giovannucci E, Pollak M, Stampfer M. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF-1) and IGF-binding protein-3. J Natl Cancer Inst 91:2052, 1999.
63. Ma J, Pollack MN, Giovannucci E, Chan JM, Tao T, Hennekens CH, Stampfer MJ. Prospective study of colorectal risk in men and plasma levels of insulin-like growth factor (IGF-1) and IGF-binding protein-3. J Natl Cancer Inst 91:620-625, 1999.
64. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z-W, Karin M, Shoelson SE. Diet-induced insulin resistance with salicylates or targeted disruption of lkkβ. Science 293:1673-1677, 2001.
65. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326, 2002.
66. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072, 2001.
67. Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 55:932-943, 1999.
68. Pineta Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor α in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 10:151-159, 1999.
69. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. Loss-of-function mutations in PPAR-γ associated with human colon cancer. Mol Cell 3:799, 1999.
70. Kitamura S, Miyazaki Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor-γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90:75-80, 1999.
71. Spencer NF, Poynter ME, Im SY, Daynes RA. Constitutive activation of NF-κB in an animal model of aging. Int Immunol 9:1581-1588, 1997.
72. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91:542-547, 1999.
73. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 147:816-825, 1998.
74. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, hyperinsulinemia hypothesis. Br J Cancer 84:417-422, 2001.
75. Kono S, Honjo S, Todoroki I, Nishiwaki M, Hamada H, Nishikawa H, Koga H, Ogawa S, Nakagawa K. Glucose intolerance and adenomas of the sigmoid colon in Japanese men (Japan). Cancer Causes Control 9:441-446, 1998.
76. La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomark Prev 6:1007-1010, 1997.
77. Barzilai N, Gabriely I. The role of fat depletion in the biological benefits of caloric restriction. J Nutr 131:903S-906S, 2001.
78. Slattery ML, Benson J, Berry DT, Duncan D, Edwards SL, Caan BJ, Potter JD. Dietary sugar and colon cancer. Cancer Epidemiol Biomark Prev 6:677-685, 1997.
79. Brand-Miller JC. Importance of glycemic index in diabetes. Am J Clin Nutr 59:747S-752S, 1994.
80. Le Floch JP, Baudin E, Escuyer P, Wirquin E, Nillus P, Perlemuter L. Influence of non-carbohydrate foods on glucose and insulin responses to carbohydrates of different glycemic index in type 2 diabetic patients. Diabet Med 9:44-48, 1992.
81. Stamp D, Zhang XM, Medine A, Bruce WR, Arder ML. Sucrose enhancement of the early steps of colon carcinogenesisin mice. Carcinogenesis (Lond) 14:777-779, 1993.
82. Luceri C, Caderni G, Lancioni L, Aiolli S, Dolara P, Mastrandrea V, Scadazza F, Morozzi G. Effects of repeated boluses of sucrose on proliferation and on AOM-induced aberrant crypt foci in rat colon. Nutr Cancer 25:187-196, 1996.
83. Carderni G, Lancioni L, Luceri C, Giannini A, Lodovici M, Biggeri A, Dolara P. Dietary sucrose and starch affect dysplastic characteristics in carcinogen-induced aberrant crypt foci in rat colon. Cancer Lett 114:39-41, 1997.
84. Bostick RM, Potter JD, Kush TA, Seller TA, Sternmetz KA, McKenzie DR, Gaspstur SM, Folson AR. Sugar, meat and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control 5:38-52, 1994.
85. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A, Savage PJ. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91:1147-1154, 1999.
86. Giovannucci E, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity and risk of colorectal adenoma in women (United States). Cancer Causes Control 7:253-263, 1996.
87. Franceschi S, Dal Maso L, Augustin L, Negri E, Parpinel M, Boyle P, Jenkins DJ, La Vecchia C. Dietary glycemic load and colorectal cancer risk. Ann Oncol 12:173-178, 2001.
88. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomark Prev 10:937-941, 2001.
89. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO, Mantzoros C. IGF-1 and IGF-2 in relation to colorectal cancer. Int J Cancer 83:15-17, 1999.
90. Giovannucci E, Pollack MN, Platz EA, Willet WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomark Prev 9:345-349, 2000.
91. Barzilay J, Heatley GJ, Cushing GW. Benign and malignant tumors in patients with acromegaly. Arch Intern Med 151:1629-1632, 1991.
92. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer. Cancer 68:1673-1677, 1991.
93. Pines A, Rozen P, Ron E, Gliat T. Gastrointestinal tumors in acromegalic patients. Am J Gastroenterol 80:266-269, 1985.
94. Cheung NW, Boyages SC. Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol 47:323-327, 1997.
95. Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, Wass JA, Besser M. Acromegaly, colonic polyps, and carcinoma. Clin Endocrinol 47:17-22, 1997.
96. Cat A, Dullaart R, Kleibeuker J, Kuipers F, Sluiter W, Hardonk M, de Vries E. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 56:523-526, 1996.
97. Jenkins PJ. Acromegaly and colon cancer. Growth Horm IGF Res 10(A):S35-S36, 2000.
98. Orme SM, McNally RJO, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort sutdy. J Clin Endocrinol Metab 83:2730-2734, 1998.
99. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V, Eyre H. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Update 2001: testing for early lung cancer detection. CA Cancer J Clin. 51:38-75; quiz 77-80, 2001.
100. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002.
101. Rigas B, Williams JL. NO-releasing NSAIDs and colon cancer chemoprevention: a promising novel approach. Int J Oncol 20:885-890, 2002.
102. Rigas B, Shiff SJ. Inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med Hypotheses 54:210-215, 2000.
103. Terry P, Giovannucci E, Michels KB, Bergkvist L, Hansen H, Holmberg L, Wolk A. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst 93:525-533, 2001.
104. Levi F, Pasche C, La Vecchia C, Lucchini F, Franceschi S. Food groups and colorectal cancer risk. Br J Cancer 79:1283-1287, 1999.
105. Giacosa A, Franceschi S, La Vecchia C, Favero A, Andreatta R. Energy intake, overweight, physical exercise and colorectal can risk. Eur J Cancer Prev 8:S53-S60, 1999.
106. Kono S, Handa K, Hayabuchi H, Kiyohara C, Inoue H, Marugame T, Shinomiya S, Hamada H, Onuma K, Koga H. Obesity, weight gain and risk of colon adenomas in Japanese men. Jpn J Cancer Res 90:805-811, 1999.
107. Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking alcohol use and diabetes with the risk of colorectal cancer. Cancer Res 57:4787-4794, 1997.